PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging

European Urology

Volumn 54, Issue 5, 2008, Pages 1073-1080

  Loeb, Stacy ^a   Kettermann, Anna ^a   Ferrucci, Luigi ^b   Landis, Patricia ^a   Metter, E Jeffrey ^b   Carter, H Ballentine ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Prognosis; Prostate cancer; PSA doubling time; PSA kinetics; PSA velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGING; ARTICLE; DIAGNOSTIC VALUE; HIGH RISK PATIENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BALTIMORE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 55649123911     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.06.076     Document Type: Article

References (18)

1. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
2. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
3. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521-1527
4. D'Amico A.V., Moul J.W., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
5. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
6. Sengupta S., Myers R.P., Slezak J.M., Bergstralh E.J., Zincke H., and Blute M.L. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174 (2005) 2191-2196
7. Freedland S.J., Dorey F., and Aronson W.J. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 57 (2001) 476-480
8. Khatami A., Aus G., Damber J.E., Lilja H., Lodding P., and Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120 (2007) 170-174
9. Klotz L. Active surveillance for prostate cancer: for whom?. J Clin Oncol 23 (2005) 8165-8169
10. Hanley J.A., and Hajian-Tilaki K.O. Sampling variability of nonparametric estimates of the areas under receiver operating characteristic curves: an update. Acad Radiol 4 (1997) 49-58
11. D'Amico A.V., Renshaw A.A., Sussman B., and Chen M.H. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
12. McLaren D.B., McKenzie M., Duncan G., and Pickles T. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 82 (1998) 342-348
13. Carter C.A., Donahue T., Sun L., et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21 (2003) 4001-4008
14. Carter H.B. Editorial comment on: Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJLH, Schröder FH. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 51 (2007) 1244-1251
15. Perrin P. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence. Eur Urol 49 (2006) 418-419
16. Song H.H. Analysis of correlated ROC areas in diagnostic testing. Biometrics 53 (1997) 370-382
17. Carter H.B. Editorial comment on: Schröder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH. Does PSA velocity predict prostate cancer in pre-screened populations?. Eur Urol 49 (2006) 460-465
18. Connolly D., Black A., Murray L.J., Napolitano G., Gavin A., and Keane P.F. Methods of calculating prostate-specific antigen velocity. Eur Urol 52 (2007) 1044-1051